CVRx beats Q3 revenue expectations, gross margin climbs

CVRx

05/11/2025 22:36

Overview

CVRx Q3 2025 revenue grows 10% yr/yr, beating analysts' expectations

U.S. revenue for Q3 2025 increases 10% yr/yr, driven by Barostim awareness

Gross margin rises to 87% in Q3 2025 due to higher selling prices, efficiencies

Outlook

CVRx expects full-year 2025 revenue between $55.6 mln and $56.6 mln

Company forecasts Q4 2025 revenue between $15.0 mln and $16.0 mln

CVRx raises full-year 2025 gross margin guidance to 85%-86%

Result Drivers

U.S. GROWTH - Expansion into new sales territories and increased Barostim awareness drove 10% revenue growth in the U.S.

IMPLANTING CENTERS - Active implanting centers in the U.S. grew to 250, supporting higher implant volumes

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$14.69 mln
$14.20 mln (7 Analysts)
Q3 EPS
-$0.49
Q3 Net Income
-$12.87 mln
Q3 Gross Margin
87.00%
Q3 Basic EPS
-$0.49
Q3 Gross Profit
$12.75 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for CVRx Inc is $12.00, about 16.8% above its November 4 closing price of $9.99

Press Release: ID:nGNX85Lwz5

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)